• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.频繁复发的生殖器疱疹的抑制作用：阿昔洛韦与异丙肌苷比较
Genitourin Med. 1989 Apr;65(2):103-5. doi: 10.1136/sti.65.2.103.
2
Treatment of first-attack genital herpes--acyclovir versus inosine pranobex.初发性生殖器疱疹的治疗——阿昔洛韦与异丙肌苷比较
Lancet. 1987 May 23;1(8543):1171-3. doi: 10.1016/s0140-6736(87)92144-1.
3
Comparative studies of inosine pranobex and acyclovir.肌苷普拉诺贝和阿昔洛韦的对比研究。
Am J Med. 1988 Aug 29;85(2A):7-9.
4
Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients.肌苷普拉诺贝与阿昔洛韦治疗中国患者复发性唇疱疹和复发性生殖器疱疹的多中心随机研究。
J Dermatol. 2015 Jun;42(6):596-601. doi: 10.1111/1346-8138.12845. Epub 2015 Mar 26.
5
Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection.阿昔洛韦与异丙肌苷（免疫病毒）用于抑制复发性单纯疱疹生殖器感染的比较。
Genitourin Med. 1992 Oct;68(5):312-6. doi: 10.1136/sti.68.5.312.
6
Long-term oral acyclovir treatment prevents recurrent genital herpes.长期口服阿昔洛韦治疗可预防复发性生殖器疱疹。
Dermatologica. 1986;173(5):220-3. doi: 10.1159/000249257.
7
Inosiplex in recurrent herpes simplex infection.肌苷在复发性单纯疱疹感染中的应用。
Lancet. 1982 Oct 23;2(8304):926. doi: 10.1016/s0140-6736(82)90884-4.
8
Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes.一项双盲、安慰剂对照试验，比较长期抑制性治疗与短期口服阿昔洛韦治疗复发性生殖器疱疹的效果。
Am J Med. 1988 Aug 29;85(2A):20-5.
9
Inosine pranobex for mucocutaneous herpes.肌苷普拉诺贝用于治疗黏膜皮肤疱疹。
Lancet. 1985 Mar 16;1(8429):631-2. doi: 10.1016/s0140-6736(85)92161-0.
10
Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial.阿昔洛韦长期抑制频繁复发的生殖器单纯疱疹病毒感染。一项多中心双盲试验。
JAMA. 1988 Jul 8;260(2):201-6.

引用本文的文献

1
Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.肌苷普拉诺昔布作为一种潜在的免疫调节剂值得关注，以实现 COVID-19 病程的早期改变。
Viruses. 2021 Nov 9;13(11):2246. doi: 10.3390/v13112246.
2
Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.肌苷普乐安：对抗多种病毒感染和非传染性疾病的关键药物。
Adv Ther. 2019 Aug;36(8):1878-1905. doi: 10.1007/s12325-019-00995-6. Epub 2019 Jun 5.
3
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.免疫功能正常的非妊娠患者预防生殖器疱疹发作的口服抗病毒治疗。
Cochrane Database Syst Rev. 2014 Aug 3;2014(8):CD009036. doi: 10.1002/14651858.CD009036.pub2.
4
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.阿昔洛韦。对其抗病毒活性、药代动力学特性及治疗效果的重新评估。
Drugs. 1994 Jan;47(1):153-205. doi: 10.2165/00003495-199447010-00009.
5
Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection.阿昔洛韦与异丙肌苷（免疫病毒）用于抑制复发性单纯疱疹生殖器感染的比较。
Genitourin Med. 1992 Oct;68(5):312-6. doi: 10.1136/sti.68.5.312.

本文引用的文献

1
Genital herpes: hype or hope?生殖器疱疹：炒作还是希望？
Br Med J (Clin Res Ed). 1983 Jun 4;286(6380):1767-8. doi: 10.1136/bmj.286.6380.1767.
2
Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.复发性生殖器疱疹的抑制作用。口服阿昔洛韦的安慰剂对照双盲试验。
N Engl J Med. 1984 Jun 14;310(24):1545-50. doi: 10.1056/NEJM198406143102401.
3
Inosiplex in recurrent herpes simplex infections.肌苷片治疗复发性单纯疱疹感染
Lancet. 1982 Aug 7;2(8293):331-2. doi: 10.1016/s0140-6736(82)90300-2.
4
Prophylactic oral acyclovir in recurrent genital herpes.
Lancet. 1984 Jul 14;2(8394):57-9. doi: 10.1016/s0140-6736(84)90237-x.
5
Antiviral activity of isoprinosine in vitro and in vivo.异丙肌苷的体内外抗病毒活性。
Am J Med Sci. 1973 Feb;265(2):143-6. doi: 10.1097/00000441-197302000-00005.
6
Acyclovir prophylaxis of recurrent genital herpes: randomised placebo controlled crossover study.阿昔洛韦预防复发性生殖器疱疹：随机安慰剂对照交叉研究。
Genitourin Med. 1985 Dec;61(6):387-90. doi: 10.1136/sti.61.6.387.
7
Recurrent genital herpes: clinical and virological features in men and women.复发性生殖器疱疹：男性和女性的临床及病毒学特征
Genitourin Med. 1988 Apr;64(2):103-6. doi: 10.1136/sti.64.2.103.
8
Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes.
Lancet. 1988 Apr 23;1(8591):926-8. doi: 10.1016/s0140-6736(88)91725-4.
9
Laboratory testing on cerebrospinal fluid. A reappraisal.脑脊液的实验室检测。重新评估。
Lancet. 1987 Jan 3;1(8523):1-4. doi: 10.1016/s0140-6736(87)90698-2.
10
Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo-controlled, crossover study.口服阿昔洛韦抑制复发性生殖器疱疹：一项双盲、安慰剂对照、交叉研究。
Acta Derm Venereol. 1985;65(1):59-63.

频繁复发的生殖器疱疹的抑制作用：阿昔洛韦与异丙肌苷比较

Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.

作者信息

Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P

机构信息

Academic Department of Genitourinary Medicine, University College and Middlesex School of Medicine, London.

出版信息

Genitourin Med. 1989 Apr;65(2):103-5. doi: 10.1136/sti.65.2.103.

DOI:10.1136/sti.65.2.103
PMID:2473952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1194297/
Abstract

The suppressive action of acyclovir and inosine pranobex was compared in a randomised double blind controlled trial in patients with frequently recurring genital herpes. Fourteen patients received acyclovir and 17 inosine pranobex. Treatment continued for 12 weeks. The time to the first recurrence was significantly longer and the frequency of recurrences significantly less in the recipients of acyclovir. No important side effects were noted. It is concluded that acyclovir is the treatment of choice to suppress often recurring genital herpes.

摘要

在一项针对复发性生殖器疱疹患者的随机双盲对照试验中，比较了阿昔洛韦和异丙肌苷的抑制作用。14名患者接受阿昔洛韦治疗，17名患者接受异丙肌苷治疗。治疗持续12周。阿昔洛韦治疗组患者首次复发的时间明显延长，复发频率明显降低。未观察到严重的副作用。结论是，阿昔洛韦是抑制复发性生殖器疱疹的首选治疗药物。